Immunogenicity in previously vaccinated adults after COVID-19 infectio
Completed
- Conditions
- Immunogenicity from COVID-19 infection might not different from the immunogenicity of booster vaccination.COVID-19
- Registration Number
- TCTR20220712001
- Lead Sponsor
- Ratchadapiseksompotch Research Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
1. 18-60 years old
2. Can comply with the trial
3. Either had been infected with COVID-19 after vaccination or had a booster dose of vaccination
Exclusion Criteria
1. Received any other vaccines within 4 months prior
2. Received blood or blood product or immunoglobulin within 3 months
3. In a high-level immunosuppression stage
4. Received monoclonal antibody, JAK inhibitor or convalescent plasma for COVID-19
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Seroconversion rate by neutralizing antibody 3 and 6 months after infection or booster dose vaccination cPass SARS-CoV-2 Neutralization Antibody Detection Kit GenScript
- Secondary Outcome Measures
Name Time Method Seroconversion rate by SARS-CoV2 antibody 3 and 6 months after infection or booster dose vaccination Enzyme-Linked Immunosorbent Assay (ELISA),Immunogenicity to variant strain 3 and 6 months after infection or booster dose vaccination Neutralization Antibody